Aplicación de la Escala de Tabaquismo para Atención Primaria (ETAP) en la práctica clínica / Application of the Smoking Scale for Primary Care (ETAP) in clinical practice

OBJETIVO: Averiguar si la escala de tabaquismo ETAP, que mide la exposición acumulada al tabaco tanto activa como pasivamente, es aplicable y efectiva en la práctica clínica de la atención primaria para la prevención del infarto agudo de miocardio (IAM). Emplazamiento Centro de salud de Barranco Grande, en Tenerife. DISEÑO: Estudio de 61 casos (IAM) y 144 controles. Muestreo con arranque aleatorio, sin apareamiento. Se realizó análisis de curvas COR-II y se estimó la efectividad mediante sensibilidad y valor predictivo negativo (VPN). Se administró una encuesta a los médicos de familia participantes sobre la aplicabilidad de la ETAP en la consulta. RESULTADOS: La opinión de los médicos participantes fue unánimemente favorable: la ETAP fue de fácil uso en la consulta, necesitó menos de 3 min por paciente y resultó útil para reforzar la intervención preventiva. La curva COR-II de la ETAP mostró que 20 años de exposición era el mejor punto de corte, con un área bajo la curva de 0,70 (IC 95%: 0,62-0,78) y una combinación de sensibilidad (98%) y VPN (96%) para el IAM. Al estratificar edad y sexo, en todos los grupos se alcanzaron sensibilidades y VPN cercanos al 100%, salvo en los hombres de edad ≥ 55años, en quienes el VPN cayó hasta el 75%. CONCLUSIONES: Los resultados apuntan a que ETAP es una herramienta válida que puede ser aplicable y efectiva en la práctica clínica de la atención primaria para la prevención del IAM relacionado con el consumo de tabaco

OBJECTIVE: To determine if the ETAP smoking scale, which measures accumulated exposure to tobacco, both actively and passively, is applicable and effective in the clinical practice of Primary Care for the prevention of acute myocardial infarction (AMI). Location Barranco Grande Health Centre in Tenerife, Spain. DESIGN: A study of 61 cases (AMI) and 144 controls. Sampling with random start, without matching. COR-II curves were analysed, and effectiveness was estimated using sensitivity and negative predictive value (NPV). A questionnaire was provided to participating family physicians on the applicability of ETAP in the clinic. RESULTS: The opinion of the participating physicians was unanimously favourable. ETAP was easy to use in the clinic, required less than 3 min per patient, and was useful to reinforce the preventive intervention. The ETAP COR-II curve showed that 20 years of exposure was the best cut-off point, with an area under the curve of 0.70 (95%CI: 0.62-0.78), and a combination of sensitivity (98%) and NPV (96%) for AMI. When stratifying age and gender, all groups achieved sensitivities and NPVs close to 100%, except for men aged ≥ 55years, in whom the NPV fell to 75%. CONCLUSIONS: The results indicate that ETAP is a valid tool that can be applied and be effective in the clinical practice of Primary Care for the prevention of AMI related to smoking exposure

[Application of the Smoking Scale for Primary Care (ETAP) in clinical practice]. / Aplicación de la Escala de Tabaquismo para Atención Primaria (ETAP) en la práctica clínica.

OBJECTIVE: To determine if the ETAP smoking scale, which measures accumulated exposure to tobacco, both actively and passively, is applicable and effective in the clinical practice of Primary Care for the prevention of acute myocardial infarction (AMI). Location Barranco Grande Health Centre in Tenerife, Spain. DESIGN: A study of 61 cases (AMI) and 144 controls. Sampling with random start, without matching. COR-II curves were analysed, and effectiveness was estimated using sensitivity and negative predictive value (NPV). A questionnaire was provided to participating family physicians on the applicability of ETAP in the clinic. RESULTS: The opinion of the participating physicians was unanimously favourable. ETAP was easy to use in the clinic, required less than 3min per patient, and was useful to reinforce the preventive intervention. The ETAP COR-II curve showed that 20years of exposure was the best cut-off point, with an area under the curve of 0.70 (95%CI: 0.62-0.78), and a combination of sensitivity (98%) and NPV (96%) for AMI. When stratifying age and gender, all groups achieved sensitivities and NPVs close to 100%, except for men aged ≥55years, in whom the NPV fell to 75%. CONCLUSIONS: The results indicate that ETAP is a valid tool that can be applied and be effective in the clinical practice of Primary Care for the prevention of AMI related to smoking exposure.